<div id="readability-page-1"><p>Fresenius SE &amp; Co. (OTCMKTS:FSNUY - Get Free Report) is anticipated to issue its resultson Wednesday, May 6th. Analysts expect the company to announce earnings of $0.2542 per share and revenue of $6.8176 billion for the quarter.</p><div><p><span></span><span>Get <strong>Fresenius SE &amp; Co.</strong> alerts:</span></p></div><p>Fresenius SE &amp; Co. (OTCMKTS:FSNUY - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.28 earnings per share for the quarter. Fresenius SE &amp; Co. had a return on equity of 10.31% and a net margin of 5.71%.The firm had revenue of $6.94 billion for the quarter.  On average, analysts expect Fresenius SE &amp; Co. to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year. </p><h2>Fresenius SE &amp; Co. Trading Up 0.9%</h2><p>Shares of FSNUY stock opened at $11.98 on Wednesday. The business's fifty day moving average price is $13.40 and its 200 day moving average price is $14.21. Fresenius SE &amp; Co. has a 1-year low of $11.67 and a 1-year high of $33.93. The firm has a market capitalization of $26.99 billion, a PE ratio of 19.02 and a beta of 0.81. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.32 and a quick ratio of 1.00. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of brokerages have issued reports on FSNUY. Morgan Stanley  reaffirmed an &#34;overweight&#34; rating on shares of Fresenius SE &amp; Co. in a report on Monday, April 20th. Citigroup  restated a &#34;buy&#34; rating on shares of Fresenius SE &amp; Co. in a report on Tuesday, February 3rd. Three analysts have rated the stock with a Buy rating,  According to MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34;.</p><p><b>Read Our Latest Stock Report on Fresenius SE &amp; Co.</b></p><h2>About Fresenius SE &amp; Co.</h2> (Get Free Report)<p>Fresenius SE &amp; Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE &amp; Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.  </p><p>The company operates through four main business segments.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Fresenius SE &amp; Co.</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPUZTTlVZ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPUZTTlVZ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Fresenius SE &amp; Co. Right Now?</h2><p>Before you consider Fresenius SE &amp; Co., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE &amp; Co. wasn't on the list.</p><p>While Fresenius SE &amp; Co. currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

FSNUY

<p>Fresenius SE & Co. (OTCMKTS:FSNUY) is set to release its quarterly earnings on May 6, with analysts predicting earnings of $0.2542 per share and revenue of $6.8176 billion. The company reported $0.28 earnings per share and $6.94 billion in revenue in the previous quarter. Currently, FSNUY shares are trading at $11.98, with a market cap of $26.99 billion. Analysts maintain a "Buy" rating on the stock, with expectations of $1 EPS for the current and next fiscal year.</p>

Market Beat

Fresenius

Fresenius SE & Co. KGaA

Morgan Stanley

Citigroup

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Fresenius SE & Co. (FSNUY) Projected to Post Quarterly Earnings on Wednesday